Therapeutic Action
Antifibrinolytic
PDF page 315
Loading InternPractice…
Drug reference
Antifibrinolytic
PDF page 315
Abnormal uterine bleeding (especially functional uterine bleeding unrelated to pregnancy)
PDF page 315
Do not administer in patients with (or with history of) venous or arterial thromboembolic disorders, severe renal impairment, history of seizures. Reduce dosage in patients with mild to moderate renal impairment (risk of accumulation). May cause: gastrointestinal disturbances, seizures with high doses, visual disturbances, allergic reactions. Avoid combination with drugs that increase the risk of thromboembolism. Concomitant use of oestrogens (e.g. ethinylestradiol/levonorgestrel) should be carefully considered on a case-by-case basis. Pregnancy: this drug is not indicated in the event of bleeding during pregnancy. Breast-feeding: no contra-indication
PDF page 315
500 mg tablet
PDF page 315
Adolescent and adult: 1 g 3 times daily (max. 1 g 4 times daily) until bleeding stops (max. 5 days)
PDF page 315
The treatment may be administered at each bleeding episode. In situations of repeated bleeding, it may be helpful to combine tranexamic acid with a non-steroidal anti-inflammatory drug and/or a long-term treatment with a levonorgestrel intrauterine device or ethinylestradiol/levonorgestrel or oral or injectable medroxyprogesterone.
PDF page 315
Below 25 °C
PDF page 316
1 g 3 times daily (max. 1 g 4 times daily) until bleeding stops (max. 5 days)
PDF page 315